Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 20 of 20 entries
View as:

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Phase: N/A Priority: Normal
NCT ID: NCT05667142 Org: User:
Start: 02/14/23 End: 10/31/25 Due: 10/31/26

An Open-label Study of XEN1101 in Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT05718817 Org: User:
Start: 04/25/23 End: 09/30/28 Due: 09/30/29

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Phase: N/A Priority: Normal
NCT ID: NCT05716100 Org: User:
Start: 05/09/23 End: 12/31/25 Due: 12/31/26

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06775379 Org: User:
Start: 12/20/24 End: 10/31/26 Due: 10/31/27

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Phase: N/A Priority: Normal
NCT ID: NCT04912856 Org: User:
Start: 08/17/21 End: 11/17/23 Due: 11/17/24

An Open-Label Study of Azetukalner in Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06922110 Org: User:
Start: 03/18/25 End: 03/31/27 Due: 03/31/28

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Phase: N/A Priority: Normal
NCT ID: NCT01195636 Org: User:
Start: 08/31/10 End: 03/31/11 Due: 03/31/12

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Phase: N/A Priority: Normal
NCT ID: NCT00954356 Org: User:
Start: 09/30/09 End: 12/31/09 Due: 12/31/10

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Phase: N/A Priority: Normal
NCT ID: NCT04952467 Org: User:
Start: 07/14/21 End: 10/04/21 Due: 10/04/22

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT05376150 Org: User:
Start: 05/19/22 End: 10/16/23 Due: 10/16/24

A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

Phase: N/A Priority: Normal
NCT ID: NCT02656043 Org: User:
Start: 09/17/15 End: 03/17/17 Due: 03/17/18

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03796962 Org: User:
Start: 01/30/19 End: 10/31/28 Due: 10/31/29

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Phase: N/A Priority: Normal
NCT ID: NCT04639310 Org: User:
Start: 03/29/21 End: 05/16/23 Due: 05/16/24

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Phase: N/A Priority: Normal
NCT ID: NCT03340220 Org: User:
Start: 11/13/17 End: 11/26/21 Due: 11/26/22

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

Phase: N/A Priority: Normal
NCT ID: NCT03467100 Org: User:
Start: 02/19/18 End: 12/19/18 Due: 12/19/19

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Phase: N/A Priority: Normal
NCT ID: NCT03468725 Org: User:
Start: 02/13/18 End: 07/31/18 Due: 07/31/19

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Phase: N/A Priority: Normal
NCT ID: NCT05614063 Org: User:
Start: 11/18/22 End: 02/28/26 Due: 02/28/27

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Phase: N/A Priority: Normal
NCT ID: NCT01090622 Org: User:
Start: 04/30/10 End: 09/30/10 Due: 09/30/11

Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00813670 Org: User:
Start: 11/30/08 End: 07/31/09 Due: 07/31/10

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Phase: N/A Priority: Normal
NCT ID: NCT01486446 Org: User:
Start: 12/31/11 End: 05/31/12 Due: 05/31/13